Overview

Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
A randomized, placebo-controlled pilot study to determine endoscopic recurrence of Crohn's disease 12 months after curative, resective ileal or ileocolonic surgery in patients receiving post-operative infliximab or placebo
Phase:
Phase 4
Details
Lead Sponsor:
University of Pittsburgh
Collaborator:
Centocor, Inc.
Treatments:
Infliximab